Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I Disorder
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Forest Laboratories
- Study ID
- NCT02670538
- Phase
- PHASE3
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- Cariprazine — DRUGCariprazine capsule one per day orally.
- Placebo — DRUGMatching placebo capsule one per day orally.
Study Details
This study is designed to prospectively confirm the efficacy of a fixed-dose regimen of cariprazine 1.5 milligrams (mg)/day or 3 mg/day compared to placebo for treatment of the depressive episode in participants with bipolar I disorder. The safety and tolerability of the fixed-dose regimens will be evaluated.
Key Dates
- Start date
- Mar 31, 2016
- Status verified
- Feb 2019
- Primary completion
- Jan 18, 2018
- Completion
- Jan 18, 2018
Study Design
- Enrollment
- 493 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Cariprazine 3.0 mgFollowing a 7 to 14 days screening/washout period, cariprazine 1.5 milligrams (mg) capsule, one per day, orally for 2 weeks increased to cariprazine 3.0 mg capsule, one per day orally beginning on Day 15 for 4 weeks.
- Experimental: Cariprazine 1.5 mgFollowing a 7 to 14 days screening/washout period, cariprazine 1.5 mg capsule, one per day, orally for 6 weeks.
- Placebo Comparator: PlaceboFollowing a 7 to 14 days screening/washout period, matching placebo capsule, one per day, orally for 6 weeks.
Primary Outcome Measure
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) [ Time Frame: Baseline (Week 0) to Week 6 ]
Locations (42)
Find similar trials in Birmingham, AL
By condition
By specialty
Related Studies
- Evaluation of the PACE/PACENET BHL Clinical ProgramRecruiting · University of Pennsylvania · Philadelphia, Pennsylvania
- BezafibrateTreatment for Bipolar Depression: A Proof of Concept StudyPHASE2 · Recruiting · Massachusetts General Hospital · Boston, Massachusetts
- Suicidal Behavior in Patients Diagnosed With Bipolar DisorderRecruiting · Emory University · Atlanta, Georgia
- Dallas 2K: A Natural History Study of DepressionRecruiting · University of Texas Southwestern Medical Center · Dallas, Texas